169 related articles for article (PubMed ID: 20924566)
1. Chemical characterization of exhaled breath to differentiate between patients with malignant plueral mesothelioma from subjects with similar professional asbestos exposure.
de Gennaro G; Dragonieri S; Longobardi F; Musti M; Stallone G; Trizio L; Tutino M
Anal Bioanal Chem; 2010 Dec; 398(7-8):3043-50. PubMed ID: 20924566
[TBL] [Abstract][Full Text] [Related]
2. An electronic nose distinguishes exhaled breath of patients with Malignant Pleural Mesothelioma from controls.
Dragonieri S; van der Schee MP; Massaro T; Schiavulli N; Brinkman P; Pinca A; Carratú P; Spanevello A; Resta O; Musti M; Sterk PJ
Lung Cancer; 2012 Mar; 75(3):326-31. PubMed ID: 21924516
[TBL] [Abstract][Full Text] [Related]
3. Exhaled breath to screen for malignant pleural mesothelioma: a validation study.
Lamote K; Vynck M; Thas O; Van Cleemput J; Nackaerts K; van Meerbeeck JP
Eur Respir J; 2017 Dec; 50(6):. PubMed ID: 29269578
[TBL] [Abstract][Full Text] [Related]
4. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
[TBL] [Abstract][Full Text] [Related]
5. Detection of malignant pleural mesothelioma in exhaled breath by multicapillary column/ion mobility spectrometry (MCC/IMS).
Lamote K; Vynck M; Van Cleemput J; Thas O; Nackaerts K; van Meerbeeck JP
J Breath Res; 2016 Sep; 10(4):046001. PubMed ID: 27669062
[TBL] [Abstract][Full Text] [Related]
6. Exhaled Breath Analysis in Diagnosis of Malignant Pleural Mesothelioma: Systematic Review.
Töreyin ZN; Ghosh M; Göksel Ö; Göksel T; Godderis L
Int J Environ Res Public Health; 2020 Feb; 17(3):. PubMed ID: 32050546
[TBL] [Abstract][Full Text] [Related]
7. Breath Analysis for Early Detection of Malignant Pleural Mesothelioma: Volatile Organic Compounds (VOCs) Determination and Possible Biochemical Pathways.
Di Gilio A; Catino A; Lombardi A; Palmisani J; Facchini L; Mongelli T; Varesano N; Bellotti R; Galetta D; de Gennaro G; Tangaro S
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32429446
[TBL] [Abstract][Full Text] [Related]
8. Breath analysis by gas chromatography-mass spectrometry and electronic nose to screen for pleural mesothelioma: a cross-sectional case-control study.
Lamote K; Brinkman P; Vandermeersch L; Vynck M; Sterk PJ; Van Langenhove H; Thas O; Van Cleemput J; Nackaerts K; van Meerbeeck JP
Oncotarget; 2017 Oct; 8(53):91593-91602. PubMed ID: 29207669
[TBL] [Abstract][Full Text] [Related]
9. Serum concentration of integrin-linked kinase in malignant pleural mesothelioma and after asbestos exposure.
Watzka SB; Posch F; Pass HI; Flores RM; Hannigan GE; Bernhard D; Weber M; Mueller MR
Eur J Cardiothorac Surg; 2013 May; 43(5):940-5. PubMed ID: 23045294
[TBL] [Abstract][Full Text] [Related]
10. Missed opportunities to counsel patients with malignant pleural mesothelioma about causation and potential compensation.
Kuschner WG; Varma R; Flores R; Agrawal M; Guvenc-Tuncturk S
Am J Med Sci; 2012 Mar; 343(3):206-9. PubMed ID: 21817877
[TBL] [Abstract][Full Text] [Related]
11. A breath test for malignant mesothelioma using an electronic nose.
Chapman EA; Thomas PS; Stone E; Lewis C; Yates DH
Eur Respir J; 2012 Aug; 40(2):448-54. PubMed ID: 22183490
[TBL] [Abstract][Full Text] [Related]
12. [Pleural mesothelioma in barman with probable occupational exposure to asbestos].
Luisi V; Marinaccio A; Mera ES; Dario R; Licchelli B; Molinini R
G Ital Med Lav Ergon; 2007; 29(3 Suppl):640-1. PubMed ID: 18409882
[TBL] [Abstract][Full Text] [Related]
13. Genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study.
Matullo G; Guarrera S; Betti M; Fiorito G; Ferrante D; Voglino F; Cadby G; Di Gaetano C; Rosa F; Russo A; Hirvonen A; Casalone E; Tunesi S; Padoan M; Giordano M; Aspesi A; Casadio C; Ardissone F; Ruffini E; Betta PG; Libener R; Guaschino R; Piccolini E; Neri M; Musk AW; de Klerk NH; Hui J; Beilby J; James AL; Creaney J; Robinson BW; Mukherjee S; Palmer LJ; Mirabelli D; Ugolini D; Bonassi S; Magnani C; Dianzani I
PLoS One; 2013; 8(4):e61253. PubMed ID: 23626673
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of Bax and Fas ligand in erionite and asbestos induced Turkish malignant pleural mesothelioma.
Kokturk N; Firat P; Akay H; Kadilar C; Ozturk C; Zorlu F; Gungen Y; Emri S
Lung Cancer; 2005 Nov; 50(2):189-98. PubMed ID: 16043260
[TBL] [Abstract][Full Text] [Related]
15. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
Grigoriu BD; Scherpereel A; Devos P; Chahine B; Letourneux M; Lebailly P; Grégoire M; Porte H; Copin MC; Lassalle P
Clin Cancer Res; 2007 May; 13(10):2928-35. PubMed ID: 17504993
[TBL] [Abstract][Full Text] [Related]
16. Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers.
Felten MK; Khatab K; Knoll L; Schettgen T; Müller-Berndorff H; Kraus T
Int Arch Occup Environ Health; 2014 Feb; 87(2):195-204. PubMed ID: 23423281
[TBL] [Abstract][Full Text] [Related]
17. Environmental exposure to asbestos and the exposure-response relationship with mesothelioma.
Madkour MT; El Bokhary MS; Awad Allah HI; Awad AA; Mahmoud HF
East Mediterr Health J; 2009; 15(1):25-38. PubMed ID: 19469424
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
Rodríguez Portal JA; Rodríguez Becerra E; Rodríguez Rodríguez D; Alfageme Michavila I; Quero Martínez A; Diego Roza C; León Jiménez A; Isidro Montes I; Cebollero Rivas P
Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):646-50. PubMed ID: 19190155
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis of malignant pleural mesothelioma.
Jaurand MC; Fleury-Feith J
Respirology; 2005 Jan; 10(1):2-8. PubMed ID: 15691231
[TBL] [Abstract][Full Text] [Related]
20. Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease.
Cavalleri T; Angelici L; Favero C; Dioni L; Mensi C; Bareggi C; Palleschi A; Rimessi A; Consonni D; Bordini L; Todaro A; Bollati V; Pesatori AC
PLoS One; 2017; 12(5):e0176680. PubMed ID: 28472171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
